Vitamin B6 catabolism and lung cancer risk : Results from the Lung Cancer Cohort Consortium (LC3)
(2019) In Annals of Oncology 30(3). p.478-485- Abstract
Background Increased vitamin B6 catabolism related to inflammation, as measured by the PAr index (the ratio of 4-pyridoxic acid over the sum of pyridoxal and pyridoxal-5'-phosphate), has been positively associated with lung cancer risk in two prospective European studies. However, the extent to which this association translates to more diverse populations is not known. Materials and methods For this study, we included 5323 incident lung cancer cases and 5323 controls individually matched by age, sex, and smoking status within each of 20 prospective cohorts from the Lung Cancer Cohort Consortium. Cohort-specific odds ratios (ORs) and 95% confidence intervals (CIs) for the association between PAr and lung cancer risk were calculated using... (More)
Background Increased vitamin B6 catabolism related to inflammation, as measured by the PAr index (the ratio of 4-pyridoxic acid over the sum of pyridoxal and pyridoxal-5'-phosphate), has been positively associated with lung cancer risk in two prospective European studies. However, the extent to which this association translates to more diverse populations is not known. Materials and methods For this study, we included 5323 incident lung cancer cases and 5323 controls individually matched by age, sex, and smoking status within each of 20 prospective cohorts from the Lung Cancer Cohort Consortium. Cohort-specific odds ratios (ORs) and 95% confidence intervals (CIs) for the association between PAr and lung cancer risk were calculated using conditional logistic regression and pooled using random-effects models. Results PAr was positively associated with lung cancer risk in a dose-response fashion. Comparing the fourth versus first quartiles of PAr resulted in an OR of 1.38 (95% CI: 1.19-1.59) for overall lung cancer risk. The association between PAr and lung cancer risk was most prominent in former smokers (OR: 1.69, 95% CI: 1.36-2.10), men (OR: 1.60, 95% CI: 1.28-2.00), and for cancers diagnosed within 3 years of blood draw (OR: 1.73, 95% CI: 1.34-2.23). Conclusion Based on pre-diagnostic data from 20 cohorts across 4 continents, this study confirms that increased vitamin B6 catabolism related to inflammation and immune activation is associated with a higher risk of developing lung cancer. Moreover, PAr may be a pre-diagnostic marker of lung cancer rather than a causal factor.
(Less)
- author
- organization
- publishing date
- 2019
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- inflammation, lung cancer, Lung Cancer Cohort Consortium, nested case-control study, PAr, vitamin B6
- in
- Annals of Oncology
- volume
- 30
- issue
- 3
- pages
- 8 pages
- publisher
- Oxford University Press
- external identifiers
-
- pmid:30698666
- scopus:85064129265
- ISSN
- 0923-7534
- DOI
- 10.1093/annonc/mdz002
- language
- English
- LU publication?
- yes
- id
- e9447c24-a56c-4f94-8661-7375d4771ad0
- date added to LUP
- 2019-05-02 11:08:36
- date last changed
- 2024-04-02 01:53:33
@article{e9447c24-a56c-4f94-8661-7375d4771ad0,
abstract = {{<p>Background Increased vitamin B6 catabolism related to inflammation, as measured by the PAr index (the ratio of 4-pyridoxic acid over the sum of pyridoxal and pyridoxal-5'-phosphate), has been positively associated with lung cancer risk in two prospective European studies. However, the extent to which this association translates to more diverse populations is not known. Materials and methods For this study, we included 5323 incident lung cancer cases and 5323 controls individually matched by age, sex, and smoking status within each of 20 prospective cohorts from the Lung Cancer Cohort Consortium. Cohort-specific odds ratios (ORs) and 95% confidence intervals (CIs) for the association between PAr and lung cancer risk were calculated using conditional logistic regression and pooled using random-effects models. Results PAr was positively associated with lung cancer risk in a dose-response fashion. Comparing the fourth versus first quartiles of PAr resulted in an OR of 1.38 (95% CI: 1.19-1.59) for overall lung cancer risk. The association between PAr and lung cancer risk was most prominent in former smokers (OR: 1.69, 95% CI: 1.36-2.10), men (OR: 1.60, 95% CI: 1.28-2.00), and for cancers diagnosed within 3 years of blood draw (OR: 1.73, 95% CI: 1.34-2.23). Conclusion Based on pre-diagnostic data from 20 cohorts across 4 continents, this study confirms that increased vitamin B6 catabolism related to inflammation and immune activation is associated with a higher risk of developing lung cancer. Moreover, PAr may be a pre-diagnostic marker of lung cancer rather than a causal factor.</p>}},
author = {{Zuo, H. and Ueland, P. M. and Midttun and Tell, G. S. and Fanidi, A. and Zheng, W. and Shu, X. and Xiang, Y. and Wu, J. and Prentice, R. and Pettinger, M. and Thomson, C. A. and Giles, G. G. and Hodge, A. and Cai, Q. and Blot, W. J. and Johansson, M. and Hultdin, J. and Grankvist, K. and Stevens, V. L. and McCullough, M. L. and Weinstein, S. J. and Albanes, D. and Ziegler, R. G. and Freedman, N. D. and Caporaso, N. E. and Langhammer, A. and Hveem, K. and Næss, M. and Buring, J. E. and Lee, I. and Gaziano, J. M. and Severi, G. and Zhang, X. and Stampfer, M. J. and Han, J. and Zeleniuch-Jacquotte, A. and Marchand, L. L. and Yuan, J. and Wang, R. and Koh, W. and Gao, Y. and Ericson, U. and Visvanathan, K. and Jones, M. R. and Relton, C. and Brennan, P. and Johansson, M. and Ulvik, A.}},
issn = {{0923-7534}},
keywords = {{inflammation; lung cancer; Lung Cancer Cohort Consortium; nested case-control study; PAr; vitamin B6}},
language = {{eng}},
number = {{3}},
pages = {{478--485}},
publisher = {{Oxford University Press}},
series = {{Annals of Oncology}},
title = {{Vitamin B6 catabolism and lung cancer risk : Results from the Lung Cancer Cohort Consortium (LC3)}},
url = {{http://dx.doi.org/10.1093/annonc/mdz002}},
doi = {{10.1093/annonc/mdz002}},
volume = {{30}},
year = {{2019}},
}